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Introduction. Treatment of breast cancer includes surgery, drugs (hormone therapy and chemotherapy), and radiation. A
discussion of eight drug constructs for the treatment of breast cancer, derived through application of in silico optimized molecular
properties and substituent substitution, are analyzed using pattern recognition techniques. Methods and Materials. Determined
properties of these eight compounds (inclusive of doxorubicin) showed a LogP varying from 0.567 to 4.137, rotatable bonds
from 5 to 12, polar surface area from 195.1A2 to 206.1A2, and water solubility from 0.00873mg/L to 390mg/L. Analysis of
similarity (ANOSIM), hierarchical cluster analysis, and neighbor-joining cluster analysis elucidated relationships among the drugs
that are useful for pharmaceutical consideration. Results and Discussion. Although the new derivatives share the same parent
scaﬀold (doxorubicin), elucidation by analysis of similarity (ANOSIM) indicates that these assorted compounds are substantially
distinct. The number of oxygen and nitrogen atoms (hydrogen bond acceptors) remained constant at 12 for compounds.
Although violations of the Rule of ﬁve remained constant at three for all compounds, the variation of LogP and water solubility
oﬀers potentially beneﬁcial medicinal activity for this group of anticancer agents that may enhance the antitumor activity of
these anthracycline antibiotics. Hierarchical cluster analysis results clearly diﬀerentiated the parent doxorubicin from all higher
molecular weight analogs. This outcome is conﬁrmed with the use of neighbor-joining cluster analysis. Conclusion. By utilizing
in silico optimization with pattern recognition analysis, potentially advantageous analogs can be elucidated from known eﬀective
pharmaceuticals.
1.Introduction
There are various types of breast cancer that will have
diﬀerent levels of proliferation, aggressiveness, and genetic
constitution. The survival rate from breast cancer varies
depending on these three factors. Treatment includes com-
binationsofthefollowing:surgery,drugsincludinghormone
therapy,chemotherapy,andtargetedtherapies,andradiation
therapy. Doxorubicin is an anthracycline antibiotic that does
inhibit the proliferative growth of bacteria but is not applied
in that clinical treatment due to the substantial level of
toxicity to human physiology [1].
The anthracycline antibiotic doxorubicin is utilized for
the clinical treatment of other cancers such as hematological
malignancies, various carcinomas, and soft tissue sarcomas
[1–3].Thedrugdoxorubicinhasamolecularstructurethatis
light sensitive and usually administered intravenously [1–3].
Although the anthracyclines are some of the most eﬀective
anticancer agents, with eﬀectiveness against more types of
cancersthananyotherclassofchemotherapeuticagents,they
haveasubstantialproblematiccardiotoxicitythatincreasesas
survival increases [4–6].
Utilizing doxorubicin in combination with paclitaxel for
the treatment of metastatic breast cancer produces beneﬁcial
outcome with over 90% response rate [7]. The problem-
atic appearance of neutropenia and mucositis complicates
treatmentregimenandoutcomeresults.Useofanthracycline
drugs can incur congestive heart failure which can be
identiﬁed in about 20% of the patients [7]. Appearance of
mucositis and neutropenia can place dose limitations on
the use of doxorubicin, even in combination with paclitaxel
[8].2 ISRN Oncology
Other studies have shown that the application of doxoru-
bicin in liposomal form may reduce toxicity usually associ-
ated with anthracyclines [9]. The use of liposomal doxoru-
bicin with a platinum agent may beneﬁt therapy of advanced
malignant epithelial ovarian carcinoma [9]. Encouraging
results have been obtained for treatment of advanced solid
tumors by pegylated liposomal doxorubicin with paclitaxel
[10]havingareducedappearanceofneutropeniaandcardio-
toxicity, with acceptable toxicity [10]. In other studies, the
use of pegylated liposomal doxorubicin with platinum also
demonstrated decreased neurotoxicity but encouraging out-
comes for ovarian cancer patients [11].
The investigation of novel designs of anthracycline
antibiotics may beneﬁt therapeutic approaches to the treat-
ment of breast cancer. Presented here is the application of
in silico optimization with pattern recognition analysis to
improve pharmaceutical activity of already proven antineo-
plastic compounds.
2.ExperimentalSection
2.1. Molecular Modeling and Assembly of Constructs. Nu-
merical values of properties and molecular modeling
was accomplished utilizing ACD/ChemSketch modeling v.
10.00 (Advanced Chemistry Development,110 Yonge Street,
Toronto, ON, Canada M5C 1T4). Other properties: polar
surface area, violations of Rule of 5, molecular volume,
number of oxygens, nitrogens, amines, hydroxyls, and so
forthweredeterminedusingMolinspiration(Molinspiration
Cheminformatics, Nova ulica 61, SK-900 26 Slovensky Grob,
Slovak Republic). In silico structure search for substituent
replacement was accomplished using Chemical substructure
and similarity search with MolCart Chemical Data Base
(Molsoft L. L. C., 3366 North Torrey Pines Court, Suite 300,
La Jolla, Calif, USA).
2.2. Pattern Recognition and Elucidation. To identify under-
lying associations/patterns within the properties, numerical
matrix required the use of various pattern recognition
techniques. Included in the analysis is hierarchical cluster
analysis accomplished by KyPlot v. 2.0 Beta 15 (Koichi
Yoshioka 1997–2001). Neighbor-joining cluster analysis and
ANOSIM (analysis of similarity) accomplished by PAST v.
1.80 (Oyvind Hammer, D. A. T. Harper 1999–2008).
2.3. Numerical Analysis of Multivariate Data Matrix. Sta-
tistical analysis of all numerical data was performed by
Microsoft EXCEL (EXCEL 2003, 1985–2003). Correlation
analysis by Pearson r was done for some descriptors and
was accomplished by GraphPad Software (GraphPad Instat
v. 3.00 for Windows 95 GraphPad Software, San Diego, Calif,
USA).
3. Results
The parent doxorubicin molecular structure as well as
the derivatives formed from that scaﬀolding are shown in
Figure 1. All compounds retain the ﬂat planar chromophore
region of this intercalating agent for insertion between two
bases of DNA. Drug B design features an imine group
(indicated by inset arrow) replacing the former primary
amine group of the daunosamine sugar. Drugs C, D, E, F,
G, H, and I are a homologous series of derivatives having
an alkoxy group (–OR) replacing the former hydroxy ketone
functional group of doxorubicin.
Molecular descriptors for doxorubicin and the deriva-
tives considered here were determined and presented in
Table 1. The number of violations of the Rule of 5 remains
at three; an expected outcome on account of variation
occurs only on the daunosamine sugar (drug B) or the
hydroxy ketone group. The number of rotatable bonds
increases as the length of the aliphatic alkoxy substituent
as do the formula weight, molecular volume, and LogP
(becoming more lipophilic as the aliphatic alkoxy group
extends in length). The number of oxygen and nitrogen
atoms (hydrogen bond acceptors) remains constant at 12
throughout this assortment of compounds.
Outcome of cluster analysis of compounds shown in
Figure 1 is presented by 2-way dendrogram in Figure 2,
whichutilizesEuclideandistancemeasure(shortestdistance)
and single linkage clustering (the distance between two
clusters is computed as the distance between the two closest
elements in the two clusters). This analysis clearly shows that
h o m o l o g o u ss e r i e sd r u g sC ,D ,E ,F ,G ,H ,a n dIa r em o s t
similar to each other but distinct from doxorubicin. This
outcome corroborated by neighbor-joining cluster analysis
(Figure 3).
Analysis of similarity (ANOSIM) indicates these assorted
compounds are substantially distinct from doxorubicin.
4. Discussion
Alteration of substituents on the molecular structure of
biologically active agents has been shown to have substantial
eﬀects on the pharmaceutical properties [12]. Substituent
modiﬁcation can change the medicinal characteristics either
beneﬁcially or destructively in terms of clinical eﬃcacy.
Substantial number of studies have been completed showing
correlation with some structure modiﬁcations directly to
important medicinal attributes such as bioavailability, lipid
solubility, aqueous solubility, and so forth [12]. Other
investigators have previously shown a particular relevance
of LogP, formula weight, and hydrogen bonding activity to
theeﬀectivenessofdruglikeness.Examinationorscreeningof
manypotentialdrugcandidatesispossiblebystatisticalcom-
parison to already proven but related medicinal compounds.
This approach of screening drug candidates improves the
success rate for selection to drug trials and eventual full
development.
One very successful screening method is known as the
Rule of 5, in which LogP, formula weight, and hydrogen
bonding activity are taken to be some multiple of the
numeric value of ﬁve. Speciﬁcally, the criteria impute that
violation of two or more of the parameters would signal
problems in drug bioavailability. These criteria include the
following [12]: (1) a LogP value of less than 5; (2) aISRN Oncology 3
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Figure 1: Comparative structures of doxorubicin and eight analogs. Note that doxorubicin (drug A) possesses a hydroxyl ketone group (see
insert circle) that can be varied widely to form other compounds with variation in LogP and aqueous solubility. Drug B retains this hydroxy
ketone group; however, an imine group replaces the original primary amine group on the daunosamine sugar substituent (see insert arrow).
All other compounds form an alkoxy (–OR) homologous series of doxorubicin at the former hydroxy ketone group.4 ISRN Oncology
Table 1: Molecular properties of derivatives.
Drug LogP
Polar
surface area
(A2)
Molecular
weight
Number of
oxygens and
nitrogens
Number of
–OH and
–NH
Violations
of rule of
ﬁve
Number of
rotatable
bonds
Molecular
volume (A3)
Water
solubility
(mg/L)
Doxorubicin, A 0.567 206.1 543.5 12 7 3 5 459.2 92.8
B 1.39 203.9 541.5 12 6 3 5 453.4 390.0
C 1.18 195.1 557.5 12 6 3 6 476.8 10.2
D 1.55 195.1 571.6 12 6 3 7 493.5 3.15
E 2.06 195.1 585.6 12 6 3 8 510.3 0.971
F 2.62 195.1 599.6 12 6 3 9 527.1 0.299
G 3.12 195.1 613.7 12 6 3 10 543.9 0.0921
H 3.63 195.1 627.7 12 6 3 11 560.7 0.0283
I 4.13 195.1 641.7 12 6 3 12 577.5 0.00873
A2 is Angstroms2.
A3 is Angstroms3.
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Figure 2: A dendrogram plot of hierarchical cluster analysis utiliz-
ing single linkage grouping method and Euclidean distance meas-
urement. Note that this analysis clearly distinguishes drugs C, D, E,
F, G, H, and I from the parent doxorubicin (drug A). Only drug B
is determined to be highly similar to doxorubicin. Doxorubicin and
drug B are join at supercluster 1, with remaining analogs associated
to supercluster 2.
Neighbor-joining cluster analysis
Correlation similarity measure
A
B
CDE FGHI
Figure 3: Results of neighbor-joining cluster analysis show drug
A (doxorubicin) and the imine derivative drug B fall on the same
node. Homologous series derivatives C, D, E, F, G, H, and I fall
adjacently and essentially identically on a central node.
formula weight less than 500 grams/mole; (3) no more
than 10 hydrogen bond acceptors (oxygen and nitrogen
atoms); (4) no more than 4 hydrogen bond donors (–OH
and –NHn). Doxorubicin is a molecule that intercalates the
DNA molecule by way of the planar aromatic chromophore
portion of the molecule and with the daunosamine sugar
resting in a minor groove with accompanied interaction
on the ﬂanking base pairs [1–3]. To pursue a useful
modiﬁcation of doxorubicin will require maintaining the
planarchromophoreregionthateﬀectivelyrestsbetweentwo
adjacent base pairs of DNA and the sugar substituent that
successfully interacts with adjacent base pairs restraining the
molecule in position.
Homologous series of compounds have a particular
advantage of having predictable properties, and extensive
studies have shown that as the numeric series increase the
medicinal activity also increases to a maximum of six or
seven carbon chain length (–(CH2)5CH3 or –(CH2)6CH3)
[13]. Lengthening the carbon chain of the alkoxy group
(–OR) produces substantial variations in the molecular
propertiesLogP,formulaweight,rotatablebonds,molecular
volume, and water solubility.
Molecular descriptors for doxorubicin and the deriva-
tives were determined and are presented in Table 1.N u m b e r
of violations of the Rule of 5 remains at three; an expected
outcome on account of variation occurs only on the
daunosamine sugar (of drug B) or the hydroxy ketone group.
This is a known restriction for anthracyclines and explains
part of the rational for intravenous administration of this
agent. Violations of Rule of 5 do not rule out the clear
eﬀectiveness of doxorubicin. The polar surface area of all the
homologous series compounds (drugs C, D, E, F, G, H, and
I) remains constant at 195.1 Angstroms2, a value that does
not facilitate intestinal absorption [12].
Water solubility of drug B is substantially higher at
390mg/Literthanthatofdoxorubicinitselfat92.84mg/Liter.
This is apparently due to the substitution of a primary
amine group with an imine group that is covalently bonded
to the daunosamine sugar (see Figure 1). As the length
of the aliphatic alkoxy substituent increases, the waterISRN Oncology 5
solubility decreases, which actually is an expected result
caused by increased lipophilic tendency of the aliphatic
branch. Correlation Pearson r for these descriptors reveals
that LogP is directly correlated (r>0.9500) to molecular
weight, number of rotatable bonds, and molecular volume
(coeﬃcient of determination >0.9025, showing account of
more than 90% of variance). LogP is inversely correlated
to polar surface area, number of –OH and –NHn (hydrogen
bond donors), and water solubility.
Previous studies have demonstrated that values of LogP
which are 2 ± 0.7 indicate the drug can penetrate the central
nervous system [14]; this criteria include derivatives D, E,
and F. A LogP value of 1.35 favors intestinal absorption,
fulﬁlled by drug B. Colonic absorption is enabled by a LogP
value of 1.32 [14], fulﬁlled by drug B. A LogP value between
3 and 4 promotes transdermal administration, fulﬁlled by
drugs G and H.
Hierarchical cluster analysis is a pattern recognition
method that sorts the subjects (drugs here) into groupings
that follow criteria set by the investigator where the highly
similar (by molecular properties of Table 1) drugs form
distinct clusters [15]. Outcome of cluster analysis of drugs
shown in Figure 1 is presented by dendrogram in Figure 2,
utilizing Euclidean distance measure (shortest distance)
and single linkage clustering (the distance between two
clusters is computed as the distance between the two closest
elements in the two clusters). This analysis clearly shows that
h o m o l o g o u ss e r i e sd r u g sC ,D ,E ,F ,G ,H ,a n dIa r em o s t
similartoeachotherbutdistinctfromdoxorubicin.DrugBis
determined to be most similar to doxorubicin. This outcome
suggests that drug B may behave similarly to doxorubicin;
however, the homologous series (C, D, E, F, G, H, and I) are
distinctandmaydiﬀerinactivitythandoxorubicin,adesired
goal for the design of new antineoplastic agents.
Neighbor-joining cluster analysis is a bottom up clus-
tering method that is an alternative for hierarchical cluster
analysis, that was initially introduced for phylogenetic analy-
sis [16]. Analysis of Table 1 properties and using correlation
similarity measure, the results again identiﬁed drug B as
most similar to doxorubicin (drug A) (see Figure 3). The
homologous series of compounds C, D, E, F, G, H, and I are
alike and joined identically.
Although the derivatives share the same parent scaf-
fold (doxorubicin), elucidation by analysis of similarity
(ANOSIM)indicatesthattheseassortedcompoundsaresub-
stantially distinct from doxorubicin. The ANOSIM outcome
R is calculated to be 1.000 (Euclidean distance measure).
This value asserts that all compounds studied here are
distinct from the parent scaﬀolding of doxorubicin. Albeit
this conclusion discernable by inspection of some descriptor
numerical values, this algorithm conﬁrms that drugs B, C, D,
E, F, G, H, and I can be expected to express diﬀerentiation
in pharmaceutical activity and medicinal action in the
treatment of breast cancer.
Previous studies have shown that substitutions on the
sugar moiety (C-3  position) will produce agents that
express antitumor activity [17]. Other work has synthesized
compounds similar to those presented in this study that
have substituted various substituents in place of the hydroxyl
group (2-hydroxy) of the –C(O)CH2OH terminus [18].
These structures include the following: 2-thiophene acetate,
benzyl carbonate, 2-methyl sulfonyl ethyl carbonate, and
butyrate, all of which showed antitumor activity when tested
in vitro [18]. It follows that emplacement of alkoxy groups
as shown in Figure 1 will provide further useful drugs
which increases the number of pharmaceutical options in
the clinical treatment of breast cancer. These derivatives
of doxorubicin encompass pharmaceutical properties that
diversify the bioactivity of anthracycline-like anticancer
agents with the potential for favorable patient outcome.
5. Conclusion
In summation, eight derivatives of doxorubicin were eluci-
dated from the parent molecular structure of doxorubicin.
By developing derivatives of doxorubicin, the LogP values
that result suggests an improved potential for drug B
(imine derivative) to accomplish intestinal absorption and
colonic absorption. A LogP value between 3 to 4 promotes
transdermal administration, fulﬁlled by drugs G and H. For
homologous series C, D, E, F, G, H, and I, the increasing
length of the aliphatic alkoxy substituent increases the
lipophilicity (thereby increasing LogP), increases molecular
volume, and increases formula weight, but decreases water
solubility. Violations of the Rule of 5 remain at three for all
compounds. Modiﬁcations in the structure of doxorubicin
vary the LogP property and potentially change the biological
activity of these anthracycline antibiotics.
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